Arcturus Therapeutics Holdings Stock Performance
| ARCT Stock | USD 6.37 0.12 1.92% |
The firm shows a Beta (market volatility) of 0.26, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Arcturus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arcturus Therapeutics is expected to be smaller as well. At this point, Arcturus Therapeutics has a negative expected return of -1.45%. Please make sure to confirm Arcturus Therapeutics' potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arcturus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Arcturus Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in February 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 348.9 M | |
| Total Cashflows From Investing Activities | -648 K |
Arcturus Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,047 in Arcturus Therapeutics Holdings on October 7, 2025 and sell it today you would lose (1,410) from holding Arcturus Therapeutics Holdings or give up 68.88% of portfolio value over 90 days. Arcturus Therapeutics Holdings is currently does not generate positive expected returns and assumes 7.6056% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Arcturus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcturus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcturus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcturus Therapeutics Holdings, and traders can use it to determine the average amount a Arcturus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1903
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARCT |
Based on monthly moving average Arcturus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcturus Therapeutics by adding Arcturus Therapeutics to a well-diversified portfolio.
Arcturus Therapeutics Fundamentals Growth
Arcturus Stock prices reflect investors' perceptions of the future prospects and financial health of Arcturus Therapeutics, and Arcturus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcturus Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | 23.21 M | ||||
| Shares Outstanding | 28.41 M | ||||
| Price To Earning | 119.50 X | ||||
| Price To Book | 0.79 X | ||||
| Price To Sales | 1.82 X | ||||
| Revenue | 138.39 M | ||||
| EBITDA | (77.4 M) | ||||
| Cash And Equivalents | 283.49 M | ||||
| Cash Per Share | 10.67 X | ||||
| Total Debt | 28.55 M | ||||
| Debt To Equity | 0.58 % | ||||
| Book Value Per Share | 8.24 X | ||||
| Cash Flow From Operations | (59.75 M) | ||||
| Earnings Per Share | (2.46) X | ||||
| Total Asset | 344.07 M | ||||
| Retained Earnings | (448.81 M) | ||||
| Current Asset | 54.55 M | ||||
| Current Liabilities | 3.52 M | ||||
About Arcturus Therapeutics Performance
Assessing Arcturus Therapeutics' fundamental ratios provides investors with valuable insights into Arcturus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arcturus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.Things to note about Arcturus Therapeutics performance evaluation
Checking the ongoing alerts about Arcturus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcturus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcturus Therapeutics generated a negative expected return over the last 90 days | |
| Arcturus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 138.39 M. Net Loss for the year was (80.94 M) with loss before overhead, payroll, taxes, and interest of (94.39 M). | |
| Arcturus Therapeutics Holdings currently holds about 283.49 M in cash with (59.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Arcturus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Arcturus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcturus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Arcturus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcturus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcturus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcturus Therapeutics' stock. These opinions can provide insight into Arcturus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.